Congress of Clinical Rheumatology Annual Meeting

Women with osteoporosis are not being identified and treated at sufficient rates, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Vitamin D may be just one factor in the combination of “bad genes” and “bad luck” that causes autoimmune disease, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Further understanding of connective tissue disease-associated interstitial lung disease has opened doors for therapeutic options, but more work needs to be done in the field, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Research linking fluctuations in bone marrow lesions with pain fluctuations may suggest that targeting these lesions could successfully reduce osteoarthritis pain, according to a speaker at the 2020 Congress of Clinical Rheumatology-West.

IgG4-related disease treatment is expected evolve greatly over the next 3 to 5 years, with a trio of promising drugs — inebilizumab, rilzabrutinib and elotuzumab — on the horizon, according to a speaker at the 2020 Congress of Clinical Rheumatology-West.

Advances in understanding of systemic juvenile idiopathic arthritis and adult-onset Still’s disease have elucidated the impact of biologic therapies on these conditions, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

With judicious use, opioids may, in fact, have a role in managing chronic pain in the rheumatology setting, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Novel therapies are providing hope for more targeted therapy options in managing the myriad manifestations of psoriatic arthritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

A multidisciplinary approach is key to optimizing outcomes in systemic sclerosis, given the broad range of manifestations and organ systems that may be involved, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Recent landmark study results have shown that interleukin-6 blockade may be superior to prolonged prednisone therapy in giant cell arteritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.